Dicot signs development agreements with leading suppliers in formulation

Report this content

Press release: Uppsala, June 8, 2021. Dicot is preparing for the initial human clinical trials. The way in which the company´s drug candidate is administered to the subjects, so-called formulation, is of the greatest importance for the studies. Therefore, agreements have been signed with two leading companies in formulation development.

In parallel with animal studies, several activities are underway within Dicot's work to develop a potency drug with better properties than those of existing drugs. The next major milestone is human clinical trials planned to be launched during 2022.

Prior to these studies, the company needs to decide how the active substance of the drug candidate LIB-01 is to be supplied to the body, i.e., in which formulation. Dicot intends to develop a formulation that is administered subcutaneously and an oral one to evaluate which is best suited for the clinical trials.

To work with the formulation, Dicot has signed an agreement with two leading companies in the field. One in the US and one in England. Both have extensive experience and know-how and will work with two different formulations.

“An important part of the industrialization phase that Dicot initiated this year is to acquire solid and relevant expertise. It is therefore very satisfying that we now have strong partnerships with two of the world's most experienced companies in something as important as formulation”, Dicot's CEO Göran Beijer comments.

For further information, please contact:
Göran Beijer, CEO
Tel: +46 (0) 706 63 60 09

About Dicot AB                                               

Dicot is developing the drug candidate LIB-01 (formerly Libiguin), which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 1,800 shareholders. For more information, please visit www.dicot.se